AlterDiag et l’Institut Pasteur s’associent pour développer des tests de diagnostic rapide de nouvelle génération
February 25, 2025 08:28 ET
|
ALTERDIAG
PARIS, 25 févr. 2025 (GLOBE NEWSWIRE) -- AlterDiag, startup française soutenue par le fonds d’investissement Forepont Capital Partners (FCP), annonce la signature d’un partenariat stratégique...
AlterDiag, a company financially backed by Forepont Capital Partner (FCP), announces the signature of a strategic partnership with the Institut Pasteur on research and development of next generation rapid diagnostic technologies for the diagnosis of infectious diseases
February 25, 2025 08:28 ET
|
ALTERDIAG
AlterDiag & Institut Pasteur partner to develop next-gen rapid tests using VHH antibodies for infectious disease diagnosis & global health impact.
Barinthus Bio Announces Strategic Focus in Immunology and Inflammation (I&I) and Provides a Financial Update
January 10, 2025 08:00 ET
|
Barinthus Biotherapeutics
Prioritizing VTP-1000 development in celiac disease, Phase 1 data expected in mid-2025Postponing further clinical development of VTP-300 in chronic hepatitis B (CHB) until a partner is...
Barinthus Bio Promotes SNAP-TI Co-inventor, Geoffrey Lynn, M.D., Ph.D. to Chief Scientific Officer
November 25, 2024 16:01 ET
|
Barinthus Biotherapeutics
OXFORD, United Kingdom and GERMANTOWN, Md., Nov. 25, 2024 (GLOBE NEWSWIRE) -- Barinthus Biotherapeutics plc (NASDAQ: BRNS) (“Barinthus Bio”), today announced the promotion of Geoffrey Lynn, M.D.,...
Barinthus Bio Reports Third Quarter 2024 Update on Corporate Developments and Financial Results
November 06, 2024 08:00 ET
|
Barinthus Biotherapeutics
Barinthus Bio Reports Third Quarter 2024 Update on Corporate Developments and Financial Results
bioLytical Laboratories Inc. Announces Health Canada Authorization of its rapid INSTI® HCV Antibody Test for Professional Use in Canada
November 04, 2024 12:00 ET
|
bioLytical Laboratories Inc.
bioLytical Laboratories Inc. announced today the immediate availability of its INSTI® HCV Antibody Test in the Canadian market
Barinthus Bio Announces Late Breaking Presentation at AASLD 2024 – The Liver Meeting® and Attendance at November Conferences
October 31, 2024 08:00 ET
|
Barinthus Biotherapeutics
Barinthus Bio Announces Late Breaking Presentation at AASLD 2024 – The Liver Meeting® and Attendance at November Conferences
BlueWillow Biologics to Present Significant Progress on Its Novel Intranasal Vaccine Technology at World Vaccine Congress Europe
October 28, 2024 08:05 ET
|
BlueWillow Biologics
ANN ARBOR, Mich., Oct. 28, 2024 (GLOBE NEWSWIRE) -- BlueWillow Biologics, Inc., a clinical-stage biotech company pioneering the future of intranasal vaccines, today announced that the company will...
Barinthus Bio Completes Enrollment for Phase 2b HBV003 Clinical Trial in Chronic Hepatitis B and Phase 1 PCA001 Clinical Trial in Prostate Cancer
October 01, 2024 08:00 ET
|
Barinthus Biotherapeutics
Barinthus Bio Completes Enrollment for Phase 2b HBV003 Clinical Trial in Chronic Hepatitis B and Phase 1 PCA001 Clinical Trial in Prostate Cancer
Barinthus Bio Reports Second Quarter 2024 Update on Corporate Developments and Financial Results
August 08, 2024 08:00 ET
|
Barinthus Biotherapeutics
Barinthus Bio Reports Second Quarter 2024 Update on Corporate Developments and Financial Results